文献速递银屑病与炎症性皮肤病

HLA-C*06等位基因与乌司奴单抗临床应答的关系:欧洲大型真实世界队列证据

Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.
PubMed 文献 · Br J Dermatol · 2017-06-22

本研究为回顾性多中心研究,纳入4个欧洲中心2014年1月至2015年3月启动乌司奴单抗治疗且已行HLA-C*06基因分型的255例银屑病患者,用PASI评分评估基线与第4、12、28、40、52周应答。结果显示HLA-C*06阳性患者在第4周PASI 50、第12周PASI 75及第52周PASI 75的比例均高于阴性患者,支持HLA-C*06作为乌司奴单抗应答的潜在预测标志物。

要点

  • 第52周PASI 75:阳性83.7%,阴性58.8%。

核心结论

  • 在歐洲真实临床实践的大型银屑病队列中,HLA-C*06被确认为乌司奴单抗应答的潜在预测标志物。

研究设计与样本

  • 回顾性多中心研究,纳入4个欧洲中心255例已行HLA-C*06基因分型并启动乌司奴单抗治疗的银屑病患者。
  • 治疗开始时间为2014年1月至2015年3月,采用PASI评分在基线及第4、12、28、40、52周随访评估。
  • 主要终点为第4周达到PASI 50的患者比例,次要终点为第12周PASI 75与PASI 90。

主要发现

  • 第52周PASI 75在HLA-C*06阳性患者为83.7%,阴性患者为58.8%。

关键数值与推荐

  • 主要终点:第4周达到PASI 50的患者比例。
  • 次要终点:第12周达到PASI 75和PASI 90的患者比例。
  • 应答评估时间点为基线及第4、12、28、40、52周。

临床怎么用

  • 对拟用乌司奴单抗的银屑病患者,可考虑检测HLA-C*06以辅助预判早期和长期应答。
  • HLA-C*06阳性者可能更早出现PASI 50应答,阴性者应答比例较低,需加强随访评估。

局限性

  • 本研究为回顾性设计,非前瞻性随机对照试验。
  • 仅纳入已行HLA-C*06基因分型的患者,可能存在选择偏倚。
  • 原文摘要未报告PASI 90结果及统计显著性检验数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Little is known about the role of the HLA-C*06 allele in the response to psoriasis treatments. OBJECTIVES: To confirm the role of HLA-C*06 as a pharmacogenetic marker of response to ustekinumab in a new, large cohort of patients involving four European centres. METHODS: In this retrospective multicentre study we reviewed data of 255 patients with psoriasis genotyped for HLA-C*06 who started ustekinumab treatment between January 2014 and March 2015. The severity of psoriasis and response to treatment were evaluated using the Psoriasis Area and Severity Index (PASI) score at baseline and then at follow-up visits on weeks 4, 12, 28, 40 and 52. The primary end point was the proportion of patients achieving ≥ 50% reduction in PASI score (PASI 50) at week 4. A ≥ 75% reduction in PASI score (PASI 75) and a ≥ 90% reduction in the PASI score (PASI 90) after 12 weeks were secondary end points. RESULTS: At week 4, PASI 50 was seen in 71·7% of HLA-C*06-positive (C*06POS) and 35·2% of HLA-C*06-negative (C*06NEG) patients. At week 12, PASI 75 was reached by 69.1% of C*06POS patients and 40·5% of C*06NEG patients. After 52 weeks, PASI 75 was reached by 83.7% of C*06POS patients and 58.8% of C*06NEG patients. CONCLUSIONS: The results from our new, large cohort of European patients treated with ustekinumab in daily clinical practice confirm the role of HLA-C*06 as a potential predictor of response to ustekinumab.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Talamonti M, Galluzzo M, van den Reek JM, et al. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol. 2017. PMID: 28207934. doi:10.1111/bjd.15387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。